Senores Pharmaceuticals Limited (SENORES) Fair Value & Analysis
Healthcare · IN · Market cap ₹63.6B
Fair value as of: Jul 3, 2026
From 14 valuation models · updated today
Share price +32.2% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹566.80 – ₹1,382 · fair‑value band ₹319.43 – ₹532.39 · the ₹1,382 price screens above the ₹425.91 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Senores Pharmaceuticals Limited (SENORES) currently trades at ₹1,382, while our model-based Fair Value estimate is ₹425.91 — implying the stock looks roughly 69.2% overvalued today. We read business quality at 56/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Senores Pharmaceuticals Limited generated revenue of ₹6.3B at a net margin of 18.4%. Revenue grew 53.4% year over year. It earns a return on equity of 13.8%. Net debt stands at ₹3.0B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, neurology, antacid, and vitamin and mineral preparation solutions; and analgesic/anti-inflammatory/antipyretic, anti-diabetic, antimalarial, neutral supplements, and urinary tract generics, as well as management and consultancy services. The company was incorporated in 2017 and is based in Ahmedabad, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Senores Pharmaceuticals Limited reported revenue of ₹6.3B in FY2026 versus ₹141M in FY2022, a compound +159.0%/yr. Reported net income was ₹1.2B in FY2026, compounding +228.5%/yr from FY2022.
Is SENORES fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,102 | $395.92 | -64% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,944 MXN | -29% |
| AbbVie Inc ABBV | $224.94 | $109.04 | -52% |
| Roche Holding ROGN | 7,050 MXN | 5,381 MXN | -24% |
| Merck & Co MRCK34 | R$72.90 | R$13.54 | -81% |
| AstraZeneca PLC A1ZN34 | R$157.11 | R$108.37 | -31% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Senores Pharmaceuticals Limited (SENORES) undervalued?
What is the fair value of SENORES?
What is the quality score of SENORES?
What is the revenue of Senores Pharmaceuticals Limited (SENORES)?
What is the net profit margin of SENORES?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.